Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inoviq Ltd ( (AU:IIQ) ) has issued an announcement.
INOVIQ Limited announced significant advancements in its ovarian cancer diagnostic and breast cancer therapeutic programs. The EXO-OC test demonstrated 100% sensitivity for early-stage ovarian cancer detection, offering a promising non-invasive screening option. Additionally, the CAR-exosome candidate showed 88% effectiveness in killing cancer cells in vitro, indicating potential for solid tumor treatment. These developments position INOVIQ as a leader in cancer diagnostics and therapeutics, with plans to accelerate the commercial availability of its ovarian cancer test and further develop its therapeutic programs.
More about Inoviq Ltd
INOVIQ Limited is a biotechnology company focused on developing diagnostic and therapeutic solutions for cancer. The company specializes in exosome-based technologies, including the EXO-NET exosome capture technology and the EXO-OC ovarian cancer screening test. INOVIQ aims to provide innovative cancer detection and treatment options, with a market focus on oncology diagnostics and therapeutics.
Average Trading Volume: 251,704
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$40.75M
Learn more about IIQ stock on TipRanks’ Stock Analysis page.